Clearmind Medicine shares surge 38.62% premarket after entering development agreement with Polyrizon to advance intranasal MEAI formulation.

Clearmind Medicine Inc. surged 38.62% in premarket trading following the announcement of a strategic development agreement with Polyrizon Ltd. to advance an intranasal formulation of its proprietary non-hallucinogenic neuroplastogen MEAI. The collaboration aims to enhance bioavailability, therapeutic efficacy, and patient usability by leveraging Polyrizon’s hydrogel technology for targeted nasal delivery. This innovation could bypass first-pass metabolism, enabling faster absorption and lower effective doses, critical advantages for CNS-targeted therapies. The partnership aligns with Clearmind’s focus on optimizing delivery mechanisms for addiction and mental health treatments, positioning MEAI for accelerated clinical development. The market’s strong reaction reflects optimism about the potential to improve therapeutic outcomes and streamline patient administration for Clearmind’s lead candidate.